Compare Stocks

Date Range: 

 Recro PharmaCocrystal PharmaF-star TherapeuticsNervGen PharmaAssertio
SymbolNASDAQ:REPHNASDAQ:COCPNASDAQ:FSTXOTCMKTS:NGENFNASDAQ:ASRT
Price Information
Current Price$2.92$1.32$7.13$1.20$0.57
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.81.42.01.71.6
Analysis Score3.53.53.53.53.5
Community Score2.62.94.25.02.5
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.70.00.8
Earnings & Valuation Score1.90.60.60.01.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$12.00$4.75$32.33$4.00$3.50
% Upside from Price Target310.96% upside259.85% upside353.48% upside233.33% upside514.04% upside
Trade Information
Market Cap$90.56 million$94.34 million$64.88 million$74.12 million$98.87 million
Beta1.251.461.78N/A1.68
Average Volume578,68311,537,608120,11324,85314,241,701
Sales & Book Value
Annual Revenue$99.22 million$6.56 millionN/A$150,000.00$229.50 million
Price / Sales0.9114.38N/A494.160.43
Cashflow$0.57 per share$1.10 per shareN/AN/AN/A
Price / Cash5.101.20N/AN/AN/A
Book Value($0.30) per share$0.73 per share$8.62 per shareN/A$0.72 per share
Price / Book-9.731.81N/A0.79
Profitability
Net Income$-18,630,000.00$-48,170,000.00$-24,100,000.00$-4,070,000.00$-217,200,000.00
EPS$0.20($0.06)($5.88)N/A($3.07)
Trailing P/E Ratio14.60N/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-34.14%-2,938.09%N/AN/A-145.15%
Return on Equity (ROE)N/A-25.81%-104.48%-73.14%-259.36%
Return on Assets (ROA)-18.97%-23.98%-62.16%-56.59%-55.13%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.04%1.02%
Current Ratio3.95%12.59%3.62%11.21%0.80%
Quick Ratio3.17%12.59%3.62%11.21%0.69%
Ownership Information
Institutional Ownership Percentage56.34%18.71%67.80%N/A39.95%
Insider Ownership Percentage23.10%10.80%12.70%N/A2.69%
Miscellaneous
Employees1851375727
Shares Outstanding31.01 million71.47 million9.10 million61.77 million173.45 million
Next Earnings Date8/9/2021 (Estimated)5/13/2021 (Estimated)N/AN/A8/6/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Bausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza - ReutersBausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza - Reuters
reuters.com - May 8 at 12:35 AM
Bausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza - Reuters.comBausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza - Reuters.com
reuters.com - May 7 at 7:35 PM
32 Stocks Moving in Fridays Pre-Market Session Benzinga - Benzinga32 Stocks Moving in Friday's Pre-Market Session Benzinga - Benzinga
benzinga.com - May 7 at 2:34 PM
Bausch, Lupin, Assertio Headed for Antitrust Trial Over Glumetza - Bloomberg LawBausch, Lupin, Assertio Headed for Antitrust Trial Over Glumetza - Bloomberg Law
news.bloomberglaw.com - May 7 at 2:34 PM
Thinking about buying stock in Sundial Growers, Assertio, Regional Health Properties, Palantir Technologies, or Energy Transfer? - Salamanca PressThinking about buying stock in Sundial Growers, Assertio, Regional Health Properties, Palantir Technologies, or Energy Transfer? - Salamanca Press
salamancapress.com - May 7 at 2:34 PM
Assertio Advances on Q1 Numbers - Baystreet.caAssertio Advances on Q1 Numbers - Baystreet.ca
baystreet.ca - May 7 at 2:34 PM
Assertio: Q1 Earnings Snapshot - SFGateAssertio: Q1 Earnings Snapshot - SFGate
sfgate.com - May 7 at 2:34 PM
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace
investorplace.com - May 7 at 9:32 AM
3 Penny Stocks That Investors Need to Watch In 2021 | FinancialContent Business Page - Financial Content3 Penny Stocks That Investors Need to Watch In 2021 | FinancialContent Business Page - Financial Content
markets.financialcontent.com - May 7 at 9:32 AM
Global Apraxia Drug Market Trends, Application Analysis and Growth Opportunities Forecast to 2026||Cogstate Ltd, Bioanalytical Systems, Inc, Salarius Pharmaceuticals, Inc, Assertio Therapeutics, Inc, Implicit Bioscience – The Manomet Current - The Manomet CurrentGlobal Apraxia Drug Market Trends, Application Analysis and Growth Opportunities Forecast to 2026||Cogstate Ltd, Bioanalytical Systems, Inc, Salarius Pharmaceuticals, Inc, Assertio Therapeutics, Inc, Implicit Bioscience – The Manomet Current - The Manomet Current
manometcurrent.com - May 7 at 9:32 AM
Assertio Holdings (ASRT) Stock Flies After report Q1 Earnings – Own Snap - Own SnapAssertio Holdings (ASRT) Stock Flies After report Q1 Earnings – Own Snap - Own Snap
ownsnap.com - May 7 at 9:32 AM
Assertio: Q1 Earnings Snapshot - CT PostAssertio: Q1 Earnings Snapshot - CT Post
ctpost.com - May 7 at 9:32 AM
Assertio Holdings (ASRT) CEO Dan Peisert on Q1 2021 Results - Earnings Call Transcript - Seeking AlphaAssertio Holdings' (ASRT) CEO Dan Peisert on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 7 at 4:31 AM
Assertio: Q1 Earnings Snapshot - Albany Times UnionAssertio: Q1 Earnings Snapshot - Albany Times Union
timesunion.com - May 7 at 4:31 AM
Assertio Holdings Inc (ASRT) stock rallied in the after-hours after the recent announcement - Market GlobalistAssertio Holdings Inc (ASRT) stock rallied in the after-hours after the recent announcement - Market Globalist
marketglobalist.com - May 6 at 11:31 PM
Assertio: Q1 Earnings Snapshot | Illinois News | beloitdailynews.com - Beloit Daily NewsAssertio: Q1 Earnings Snapshot | Illinois News | beloitdailynews.com - Beloit Daily News
beloitdailynews.com - May 6 at 11:31 PM
Assertio Reports First Quarter 2021 Financial Results - Yahoo FinanceAssertio Reports First Quarter 2021 Financial Results - Yahoo Finance
finance.yahoo.com - May 6 at 11:31 PM
Assertio Reports First Quarter 2021 Financial Results - GlobeNewswireAssertio Reports First Quarter 2021 Financial Results - GlobeNewswire
globenewswire.com - May 6 at 6:30 PM
Assertio: Q1 Earnings Snapshot - Westport NewsAssertio: Q1 Earnings Snapshot - Westport News
westport-news.com - May 6 at 6:30 PM
Assertio Reports First Quarter 2021 Financial ResultsAssertio Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 6 at 6:30 PM
Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine) - Yahoo FinanceAssertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine) - Yahoo Finance
finance.yahoo.com - May 6 at 1:30 PM
Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA - GlobeNewswireAssertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA - GlobeNewswire
globenewswire.com - May 5 at 12:28 PM
Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine)Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine)
finance.yahoo.com - May 5 at 12:28 PM
Post herpetic Neuralgia Treatment Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players Analysis- Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, etc. - Good News GumPost herpetic Neuralgia Treatment Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players Analysis- Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, etc. - Good News Gum
goodnewsgum.com - May 3 at 2:44 PM
Assertio Holdings, Inc. (NASDAQ:ASRT) Has Been Rising 52.94% Since The Beginning Of The Year. Troubles Ahead?Assertio Holdings, Inc. (NASDAQ:ASRT) Has Been Rising 52.94% Since The Beginning Of The Year. Troubles Ahead?
marketingsentinel.com - April 30 at 2:03 PM
DateCompanyBrokerageAction
1/4/2021Recro PharmaCraig HallumInitiated Coverage
5/12/2020Recro PharmaOppenheimerLower Price Target
3/5/2020Recro PharmaStephensLower Price Target
3/25/2019Recro PharmaRoth CapitalReiterated Rating
1/31/2019Recro PharmaJanney Montgomery ScottReiterated Rating
11/8/2018Recro PharmaPiper Jaffray CompaniesSet Price Target
11/18/2020Cocrystal PharmaNoble FinancialReiterated Rating
11/12/2020Cocrystal PharmaHC WainwrightLower Price Target
7/17/2018Cocrystal PharmaEuroPacific CanadaInitiated Coverage
4/14/2021F-star TherapeuticsWilliam BlairInitiated Coverage
3/30/2021F-star TherapeuticsLaidlawInitiated Coverage
12/2/2020F-star TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
10/20/2020NervGen PharmaMaxim GroupReiterated Rating
4/13/2021AssertioGabelliUpgrade
9/18/2020AssertioG.ResearchReiterated Rating
6/3/2020AssertioBrookline Capital ManagementInitiated Coverage
5/16/2019AssertioMizuhoLower Price Target
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.